Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

4.8 (342) · $ 30.50 · In stock

Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/ dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. - Abstract - Europe PMC

OUH - Group members

Cancers, Free Full-Text

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open

Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Before Autologous Stem Cell Transplant for Multiple Myeloma

Carfilzomib as maintenance therapy after upfront and salvage ASCT

OUH - About our research

167580 PDFs Review articles in MULTIPLE MYELOMA

Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials - Transplantation and Cellular Therapy, Official Publication of the

© 2018-2024, stofnunsigurbjorns.is, Inc. or its affiliates